Watch: Are weight-loss jabs worth the side effects?

This piece dives into the latest chatter in the health care investment scene, spotlighting players like Riverstone Holdings and CSL’s vaccine division. Think of it as a quick pulse-check on where money’s flowing and which companies are making waves—whether through deals, innovations, or market moves.

Editor’s Note: For anyone tracking the business side of health care—investors, professionals, or just the financially curious—this roundup offers a snapshot of who’s up, who’s interesting, and where the sector might be headed next. It’s not breaking news, but it’s the kind of insider-ish talk that helps connect dots in a fast-moving industry.

The UK government has launched a national inquiry into maternity care, specifically focusing on England's worst-performing hospital trusts. The investigation aims to identify systemic failures and recommend improvements, with findings expected by the end of the year.

Editor’s Note: This isn't just bureaucratic noise—it’s a direct response to alarming reports of preventable harm in maternity units. For expectant parents, it signals that serious gaps in care are finally being addressed, but it also underscores how much work lies ahead to ensure safe childbirth experiences nationwide.

Novo Nordisk’s experimental obesity drug, Amycretin, has shown promising early results—helping patients shed more than 24% of their body weight in a trial. That outperforms the company’s own blockbuster drug Wegovy, which averaged around 17% weight loss. While it’s still early days, the data suggests Amycretin could be a game-changer in the booming weight-loss drug market.

Editor’s Note: Obesity treatments are big business, and Novo Nordisk is already leading the pack with Wegovy. If Amycretin keeps delivering like this in later trials, it could shake up the industry—offering patients even more effective options and tightening Novo’s grip on the market. For anyone watching the space, this is a sign that the weight-loss drug race is far from over.

Despite the Supreme Court overturning Roe v. Wade three years ago, abortions in the U.S. have actually increased—thanks largely to telemedicine and "shield laws" that protect providers in states where abortion remains legal. These laws allow doctors to prescribe abortion pills remotely, even to patients in states with strict bans, creating a kind of underground lifeline for reproductive care.

Editor’s Note: This isn’t just a story about legal battles—it’s about how people adapt when rights are restricted. Telemedicine is quietly reshaping access to abortion, proving that bans don’t always mean fewer procedures, just more creative workarounds. It also highlights the uneven patchwork of state laws and how technology can both challenge and circumvent them. For anyone tracking the real-world impact of Roe’s reversal, this is a crucial twist in the saga.

A luxury grocery store called Erewhon has somehow become a must-see stop for tourists visiting Los Angeles, rubbing shoulders with iconic attractions like the Hollywood sign and celebrity home tours. Visitors like William Rath, a recent law school grad, are adding it to their itineraries alongside classic L.A. experiences—proof that the city's culture of wellness and exclusivity has turned even a high-end supermarket into a destination.

Editor’s Note: This isn’t just about overpriced smoothies—it’s a sign of how L.A.’s obsession with status and "clean" living has blurred the line between everyday errands and aspirational experiences. If a grocery store can draw tourists, it says something about what people now associate with the city (and maybe how far they’ll go for Instagram-worthy content).